Genomtec has received patent protection from the Polish Patent Office for a primer set for the detection of Human papillomavirus-16 (HPV16), a method for detecting HPV16 infection, and an application of the primer set for detecting HPV infection.
HPV16 is one of the sexually transmitted viruses with a leading cause for cervical cancer due to persistent infections. Because of its oncogenic properties early diagnosis of HPV infection is important for prompt initiation of appropriate therapeutic procedures and further monitoring of the patient in order to reduce the risk of cancer development.
– As part of our work on Genomtec®ID, we plan to develop a diagnostics test menu for the detection of sexually transmitted diseases, including HPV, chlamydia and gonorrhoea-causing bacteria which will follow our current efforts of launching a panel for detecting respiratory diseases – the so-called 5 – plex panel. We know how important early diagnosis of sexually transmitted diseases is and the discomfort it brings to patients. Genomtec®ID is aimed to reduce this due to its point of care characteristics – said Miron Tokarski, co-founder and CEO of Genomtec SA.
Genomtec recently announced that it will accelerate its work on the commercialization of Genomtec®ID. The company also announced its intention to transfer its shares to the main market of the Warsaw Stock Exchange. To this end, on 29th October it submitted a prospectus to the Polish Financial Supervision Authority (UKNF). This week the company unveiled a demo of its solution at MEDICA- leading industry trade fair in Düsseldorf, Germany.